Purpose: A meta-analysis was performed to compare the efficacy of an anterior chamber injection of moxifloxacin in the prevention of endophthalmitis after cataract surgery.
Methods: A computer-based search of PubMed, Embase, the Cochrane Library, and the Clinical Trial database for articles related to anterior intraventricular injection of moxifloxacin for the prevention of endophthalmitis after cataract surgery was performed through April 2019. Study selection, data exclusion, and quality assessment were performed by two independent observers. Statistical analysis for the meta-analysis was performed by RevMan5.3 software.
Results: Eight studies were included, with a total of 123,819 eyes. The meta-analysis showed that an anterior chamber injection of moxifloxacin can prevent the incidence of endophthalmitis after cataract surgery (OR = 0.29, 95% CI (0.15, 0.56), =0.0002), and the difference was statistically significant. There were no significant differences between the moxifloxacin injection and nonmoxifloxacin injection groups in regard to UCVA (log MAR) (SMD = -0.13, 95% CI (-0.62, 0.35), =0.60), BCVA (log MAR) (SMD = -0.27, 95% CI (-1.28, 0.74), =0.60), IOP (SMD = -0.04, 95% CI (-0.02, 0.01), =0.22), corneal edema (OR = 1.03, 95% CI (0.23, 4.69), =0.97), CCT (SMD = -0.01, 95% CI (-0.07, 0.05), =0.77), or ECD (SMD = 0.00, 95% CI (-0.06, 0.07), =0.94).
Conclusion: An anterior chamber injection of moxifloxacin can effectively prevent the incidence of endophthalmitis after cataract surgery, while the moxifloxacin injection and nonmoxifloxacin injection groups had similar results in regard to UCVA (log MAR), BCVA (log MAR), IOP, corneal edema, CCT, and ECD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468651 | PMC |
| http://dx.doi.org/10.1155/2020/7242969 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analyses of Adverse Drug Reactions to Fluoroquinolones in Spontaneous Reports Before and After the Referral and in Clinical Routine Cases.
Drugs R D
January 2025
Research Division, Federal Institute of Drugs and Medical Devices (BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Germany.
Introduction: In November 2018, the European Medicines Agency (EMA) restricted the use of fluoroquinolones (used by mouth, injections or inhalation) in the context of a referral due to long-lasting and potentially irreversible adverse drug reactions (ADRs). Fluoroquinolones should no longer be used to treat mild or moderate bacterial infections unless other antibacterials cannot be used.
Objectives: The first aim of our study was to analyze whether in the period before compared with after the referral the characteristics of spontaneous ADR reports related to fluoroquinolones differed and whether specific ADRs were more frequently reported for fluoroquinolones compared with cotrimoxazole.
Varicella challenges: A case of respiratory tract complications in an elderly patient.
Narra J
December 2024
Department of Dermatology Venereology and Aesthetic, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Varicella, caused by the varicella-zoster virus (VZV), is rarely reported in the elderly but often complicates with pneumonia. In this case report, we present a case of varicella pneumonia in the elderly. A 60-year-old man presented to the emergency room with vesicles filled with clear fluid that had appeared all over the body for the past four days.
View Article and Find Full Text PDFAssessing the Effectiveness of a Short Injectable Treatment Regimen for Multidrug-Resistant Tuberculosis: Clinical Outcomes in Khyber Pakhtunkhwa.
Cureus
October 2024
AIDS, TB, and Malaria, Common Management Unit, Islamabad, PAK.
Background The currently recommended treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are complex, costly, prolonged (lasting at least 20 months), and often poorly tolerated. The objective of this study was to evaluate the effectiveness of the shorter treatment regimen (STR) for treating patients with MDR-TB in Khyber Pakhtunkhwa. Methodology The present study was a case series conducted at the Programmatic Management of Drug Resistant TB Unit, Lady Reading Hospital (PMDT-LRH), Khyber Pakhtunkhwa, Pakistan.
View Article and Find Full Text PDFEvaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows.
Lancet Infect Dis
October 2024
FIND, Geneva, Switzerland; Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology, University of San Diego, San Diego, CA, USA.
Background: Drug-resistant tuberculosis remains a major obstacle in ending the global tuberculosis epidemic. Deployment of molecular tools for comprehensive drug resistance profiling is imperative for successful detection and characterisation of tuberculosis drug resistance. We aimed to assess the diagnostic accuracy of a new class of molecular diagnostics for drug-resistant tuberculosis.
View Article and Find Full Text PDFA New Ray of Hope in the Treatment of Seasonal Hyperacute Panuveitis: Could Intravitreal Triple Combination Therapy of an Antibiotic with Dual Steroids Play a Pivotal Role?
Ocul Immunol Inflamm
October 2024
Department of Ophthalmology, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, B. P. Koirala Lions Centre for Ophthalmic Studies, Maharajgunj, Nepal.
Introduction: Seasonal Hyperacute Panuveitis (SHAPU) is a blinding disease in Nepal with unknown aetiology. Henceforth, we proposed to study the treatment outcome of a triple intravitreal combination therapy of dual steroids triamcinolone (long-acting steroid) and dexamethasone (short-acting steroid) along with antibiotic moxifloxacin for patients with severe stage of SHAPU.
Methods: A prospective study was conducted among the SHAPU patients presenting in severe stages during the September to December 2023 outbreak.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!